Market Outlook

By 2035, the U.S. Gastrointestinal Endoscopy Devices Market is expected to reach approximately USD 13.81 billion, expanding at a CAGR of 7.42% during 2026–2035. The market is estimated at USD 6.75 billion in 2025, following historical expansion from approximately USD 4.72 billion in 2021, USD 5.25 billion in 2022, USD 5.93 billion in 2023, and USD 6.31 billion in 2024. Values in this report are expressed in USD billions.

The U.S. gastrointestinal endoscopy devices industry sits at the intersection of cancer prevention, chronic digestive disease management, minimally invasive intervention, hospital capital equipment, and recurring procedural consumables. Demand is supported by the scale of colorectal cancer screening, upper gastrointestinal evaluation, inflammatory bowel disease surveillance, gastrointestinal bleeding management, pancreaticobiliary intervention, endoscopic ultrasound, polypectomy, tissue acquisition, dilation, stenting, and increasingly complex therapeutic endoscopy. Approximately 159,000 new colorectal cancer cases are expected in the United States in 2026, while the U.S. adult population living with diagnosed inflammatory bowel disease has risen to approximately 4.1 million. These disease pools create recurring rather than episodic demand for endoscopy infrastructure.

Growth is increasingly moving beyond conventional colonoscopes and gastroscopes. U.S. health systems are investing in high-definition and image-enhanced endoscopy, AI-assisted polyp detection, advanced endoscopic ultrasound, single-use scopes for selected procedures, lesion measurement technologies, endoscopic suturing, mucosal resection devices, hemostasis platforms, cholangioscopy, disposable accessories, and digitally connected processors. The economic value of a GI endoscopy platform is therefore shifting from image acquisition alone toward its ability to increase adenoma detection, support therapeutic procedures, reduce repeat examinations, shorten room turnover, improve traceability, minimize reprocessing risk, and standardize clinical performance across physicians.

Hospital and ambulatory procurement is also changing. Endoscopy capital committees increasingly evaluate the combined cost of processors, scopes, repair contracts, reprocessing labor, automated endoscope reprocessors, water and chemical consumption, disposable accessories, procedure-room utilization, service uptime, and physician preference. The cheapest scope or processor is not necessarily the lowest-cost solution at the service-line level. Vendors that can demonstrate lower total procedure cost, higher equipment availability, clinically relevant visualization improvements, and strong accessory compatibility are gaining influence with integrated delivery networks and large gastroenterology groups.

A major structural feature of the U.S. market is the continued migration of routine GI procedures into outpatient settings. Medicare-certified ambulatory surgical centers exceeded 6,400 facilities by the end of 2024, and upper gastrointestinal endoscopy and colonoscopy are among the most commonly performed ASC procedures. This setting shift favors systems that combine high throughput, predictable maintenance, compact footprints, simplified workflow, strong service support, and recurring consumable economics. At the same time, complex EUS, ERCP, endoscopic submucosal dissection, advanced resection, endoluminal suturing, and difficult bleeding cases continue to strengthen the role of tertiary hospitals and academic referral centers.

The market is expected to reach approximately USD 9.65 billion by 2030 before progressing toward USD 13.81 billion by 2035. Value growth will be faster than basic procedure-volume growth because of technology mix: AI modules, premium imaging, advanced therapy accessories, single-use devices, EUS-guided intervention, and higher-value endoscopic procedures are increasing the revenue captured per patient episode.

 

Introduction

According to the U.S. Gastrointestinal Endoscopy Devices Market Report, gastrointestinal endoscopy has become one of the most procedure-intensive and technology-dependent components of U.S. digestive care. The market supports screening, diagnosis, surveillance, biopsy, tissue resection, bleeding control, biliary and pancreatic intervention, stricture management, foreign-body retrieval, enteral access, and increasingly interventions that historically required surgery or interventional radiology.

For the purpose of this report, the market encompasses reusable and single-use gastrointestinal endoscopes, colonoscopes, gastroscopes, enteroscopes, sigmoidoscopes and duodenoscopes; endoscopic ultrasound systems and echoendoscopes; capsule endoscopy platforms; video processors, light sources and visualization equipment; AI-enabled endoscopy technologies; and endotherapy devices used directly during gastrointestinal endoscopic procedures. The scope includes polypectomy snares, biopsy and sampling devices, guidewires, retrieval systems, clips, injection needles, dilation balloons, gastrointestinal stents, hemostatic technologies, ablation tools and selected endoscopic closure or suturing platforms. Non-endoscopic stool and blood screening assays are excluded from the core device valuation.

The U.S. opportunity is supported by a large unresolved screening population. Colorectal cancer screening is recommended for average-risk adults beginning at age 45, yet approximately 28 million U.S. adults aged 45–75 were estimated to have never undergone colorectal cancer screening in recent national survey analysis. This is commercially important because expanding non-invasive screening does not necessarily displace endoscopy. Positive stool or blood-based screening tests create downstream colonoscopy demand, while colonoscopy retains the critical advantage of enabling diagnosis, biopsy, and polyp removal during the same procedure.

The market is also clinically diversified. Colorectal cancer provides the largest preventive endoscopy demand pool, but upper GI disorders, esophageal disease, gastrointestinal bleeding, inflammatory bowel disease, gastric abnormalities, pancreaticobiliary disorders, strictures, Barrett’s esophagus, and pancreatic or biliary malignancy contribute high-value diagnostic and therapeutic utilization. More than 500,000 ERCP procedures are performed annually in the United States, supporting a specialized ecosystem of duodenoscopes, guidewires, sphincterotomes, extraction balloons, baskets, dilation devices, biliary stents, cholangioscopy systems and infection-prevention solutions.

A second defining characteristic is recurring revenue. Capital processors and scope fleets generate the installed base, but substantial economics are captured through disposable valves, snares, forceps, clips, needles, guidewires, retrieval devices, dilation balloons, hemostatic products, stents and other procedure-specific accessories. This makes GI endoscopy strategically attractive to diversified medtech companies because capital placement can influence years of downstream accessory utilization and service revenue.

From 2026 through 2035, competitive advantage will increasingly depend on ownership of an integrated clinical workflow. Vendors that combine visualization, scopes, AI, therapeutic accessories, reprocessing support, physician education and service infrastructure can create higher switching barriers than single-product suppliers. However, specialist companies will continue to gain share where they solve narrowly defined clinical problems such as difficult polyp resection, endoscopic closure, tissue acquisition, single-use access, EUS-guided therapy, or advanced hemostasis.

 

Key Market Drivers: What’s Fueling the U.S. Gastrointestinal Endoscopy Devices Market?

The first major driver is the size of the colorectal cancer prevention opportunity. Colorectal cancer remains one of the most consequential malignancies in the United States, with approximately 158,850 new cases and more than 55,000 deaths expected in 2026. Screening provides a direct procedural pathway into GI endoscopy because colonoscopy can both detect neoplasia and remove precancerous polyps. The lowering of the recommended screening starting age to 45 materially expanded the addressable population, while screening gaps among adults aged 45–49 provide a multi-year opportunity for gastroenterology practices and endoscopy centers.

A second driver is the incomplete penetration of colorectal cancer screening. National analyses show that barely three-fifths of adults aged 45–75 were fully up to date with recommended screening when the expanded age range was evaluated, and roughly 28 million adults in the eligible population had never been screened. This represents a significant backlog rather than a saturated screening market. Greater primary-care outreach, employer screening programs, non-invasive testing, health-plan quality programs and Medicare coverage changes can ultimately increase downstream diagnostic colonoscopy referrals.

The third driver is the increasing prevalence of chronic gastrointestinal disease. Approximately 4.1 million U.S. adults were estimated to have diagnosed inflammatory bowel disease in 2023–2024. Crohn’s disease and ulcerative colitis create recurring endoscopic demand for diagnosis, mucosal assessment, dysplasia surveillance, stricture evaluation and treatment response monitoring. Unlike a single screening episode, chronic IBD can require repeated endoscopy over many years, making this patient population particularly important for advanced imaging and disease surveillance technologies.

The fourth driver is migration toward minimally invasive therapeutic endoscopy. Endoscopists are treating an expanding range of conditions without open surgery. Endoscopic mucosal resection, endoscopic submucosal dissection, full-thickness closure, endoscopic hemostasis, dilation, stenting, endoluminal suturing, EUS-guided drainage and advanced ERCP are expanding the economic role of the GI suite. This transition increases demand for high-performance scopes with larger working channels, stable visualization, precise accessory control and broad therapeutic compatibility.

The fifth driver is the expansion of ambulatory endoscopy. The United States had approximately 6,436 Medicare-certified ASCs at the end of 2024, and colonoscopy and upper gastrointestinal endoscopy remain among their most common services. The growth of ASCs changes device purchasing criteria. Freestanding centers typically operate with narrower capital budgets than tertiary hospitals but place greater emphasis on predictable throughput, room utilization, repair costs, staff productivity and procedure-level economics. Vendors able to combine competitive capital pricing with reliable scopes, responsive service and attractive disposable economics can build durable share in this channel.

A sixth driver is AI-assisted colonoscopy. Computer-aided detection is moving from a technology demonstration to a purchasing category. FDA-cleared systems can identify potential lesions in real time, providing a second layer of visual attention during colonoscopy. As gastroenterology practices become more focused on adenoma detection rate, documentation quality, quality reporting and consistency between physicians, AI may increasingly be purchased as part of a broader endoscopy platform rather than as an isolated software add-on.

The seventh driver is infection prevention and reprocessing economics. Reusable flexible endoscopes require complex cleaning, high-level disinfection, drying, storage, tracking and maintenance. Duodenoscopes have received particular attention because of their complex elevator mechanisms and potential contamination risks. FDA recommendations encouraging migration toward modern duodenoscope designs, disposable components and fully disposable scopes have created a permanent market for single-use technology. Adoption will remain selective because reusable scopes can have better economics at high volumes, but infection risk, emergency availability and reprocessing constraints make single-use systems strategically important.

An eighth driver is reimbursement alignment. Medicare’s expansion of the definition of complete colorectal cancer screening to include follow-on colonoscopy after certain positive non-invasive screening tests improves continuity between screening and definitive endoscopic evaluation. Reimbursement does not remove every access barrier, but it strengthens the clinical funnel from primary screening into colonoscopy. For manufacturers, reimbursement-linked procedure growth is particularly valuable because each incremental colonoscopy creates demand not only for scope utilization but also for biopsy, polypectomy, retrieval, hemostasis and pathology-related workflows.

 

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation in GI endoscopy is moving from incremental optics toward integrated decision support and intervention. The next generation of competitive platforms is being designed to help physicians find lesions, characterize tissue, measure abnormalities, navigate difficult anatomy, perform therapy, document results and manage procedure data within a single workflow.

AI-assisted detection is one of the most visible shifts. Computer-aided polyp detection systems analyze live endoscopic video and alert physicians to potentially suspicious mucosal areas. The commercial value is strongest when software can be integrated into existing processors without creating workflow friction. Over time, AI competition is likely to expand from detection toward characterization, lesion sizing, quality measurement, withdrawal analytics, automated documentation and procedural performance benchmarking.

Advanced image enhancement is another major innovation cycle. Narrow-band, linked-color, blue-light, texture-enhancement and red-dichromatic imaging technologies are designed to reveal vascular and mucosal characteristics that may be less apparent under conventional white-light visualization. These technologies can be strategically important in colorectal lesion detection, Barrett’s esophagus surveillance, bleeding localization and inflammatory disease assessment. For hospitals, the premium becomes easier to justify when enhanced visualization supports both diagnostic confidence and therapeutic decision-making.

Quantitative imaging is emerging as a new category. Technologies capable of providing objective lesion-size estimation address an important limitation of traditional endoscopy, where polyp measurements can vary materially between observers. Accurate sizing affects resection strategy and surveillance interval recommendations. As endoscopy becomes more data-driven, quantitative tools that standardize measurements may become increasingly important for quality assurance and clinical documentation.

Single-use gastrointestinal endoscopy is also entering a more mature phase. Early adoption was concentrated in duodenoscopy because of infection-prevention concerns, but single-use gastroscopes and other disposable platforms are broadening the discussion. The business case is strongest in low-volume facilities, emergency procedures, high-risk infections, mobile services, overflow capacity and situations where reusable scope availability is constrained by reprocessing or repair. Sustainability and per-case cost remain important counterweights, meaning that hybrid fleets rather than complete conversion are likely in many U.S. facilities.

Endoscopic ultrasound is evolving from a diagnostic modality into an interventional platform. EUS-guided tissue acquisition, pancreatic lesion evaluation, biliary access, drainage and other advanced procedures are expanding the strategic importance of echoendoscopes and ultrasound processors. Hospitals building pancreaticobiliary centers increasingly evaluate ERCP and EUS together because the procedures share physician expertise, referral networks and many accessory categories.

Therapeutic accessory innovation is equally important. Cold-snare polypectomy, advanced clips, hemostatic powders, suturing systems, lumen-apposing metal stents, biliary and enteral stents, ESD knives, injection systems and enhanced tissue-acquisition devices are increasing the treatment capability of the endoscopy suite. For manufacturers, these technologies offer attractive recurring-revenue opportunities because they are consumed at the procedure level and can be bundled with capital equipment relationships.

 

Segmentation Insights

The U.S. Gastrointestinal Endoscopy Devices Market is segmented on the basis of product type, procedure/application, technology, end user, and geography.

 

By Product Type

Reusable Flexible Gastrointestinal Endoscopes

Reusable flexible endoscopes remain the clinical foundation of the U.S. market. This category includes colonoscopes, gastroscopes, sigmoidoscopes, enteroscopes and duodenoscopes. Colonoscopes represent the largest installed fleet because of colorectal cancer screening and surveillance volumes. Gastroscopes support upper GI evaluation, bleeding management, biopsy, Barrett’s surveillance and therapeutic procedures. Duodenoscopes command a smaller unit base but carry high strategic value because they enable ERCP and require specialized infection-prevention workflows.

Premium competition increasingly centers on image quality, distal-tip design, maneuverability, working-channel performance, ergonomics, stiffness control, compatibility with enhanced imaging and durability under heavy use. Large health systems often standardize scope fleets around processor ecosystems to simplify training, maintenance and inventory.

Single-Use Gastrointestinal Endoscopes

Single-use endoscopes represent one of the fastest-growing product categories. Disposable duodenoscopes have the clearest clinical rationale because they eliminate the need to reprocess the same scope between patients. Single-use gastroscopes and related flexible scopes are creating additional demand in intensive care, emergency care, low-volume sites and facilities that require guaranteed procedure readiness.

The commercial challenge is total cost. High-volume ASCs can spread reusable scope capital and reprocessing expense across thousands of cases, whereas single-use devices create a direct per-procedure cost. Adoption will therefore be use-case driven rather than uniform. Hybrid procurement models are likely to dominate through the forecast period.

Visualization and Imaging Systems

Video processors, light sources, high-definition monitors, image-enhancement modules and integrated endoscopy systems form a major capital-equipment category. Processor placement is strategically significant because it influences future scope purchasing and can anchor a health system to a vendor ecosystem for multiple capital cycles.

The transition toward LED illumination, advanced image processing, 4K-compatible visualization and software-enabled imaging is increasing average selling value. Hospitals evaluating a replacement platform increasingly consider AI readiness, image-enhancement capabilities, interoperability, service response and compatibility with future scope generations.

Endoscopic Ultrasound and Capsule Endoscopy Systems

EUS systems include ultrasound processors, radial and linear echoendoscopes and associated tissue-acquisition devices. Demand is strongest in tertiary hospitals and high-volume pancreaticobiliary centers. EUS has become essential for pancreatic lesions, subepithelial abnormalities, biliary evaluation and targeted tissue sampling, with intervention gradually increasing its revenue contribution.

Capsule endoscopy represents a smaller but strategically differentiated market used primarily for small-bowel visualization and selected gastrointestinal indications. Improvements in image acquisition, battery life, reading software and AI-assisted interpretation can reduce physician review burden and expand clinical utility.

Endotherapy Devices and Accessories

Endotherapy products create one of the most attractive recurring-revenue pools. The category includes biopsy forceps, polypectomy snares, retrieval nets, injection needles, guidewires, dilation balloons, clips, hemostasis devices, stents, sphincterotomes, extraction balloons, baskets, cytology brushes, EUS needles, ablation devices and advanced closure tools.

Unlike capital scopes, these devices are often consumed during each procedure. Manufacturers with broad endotherapy portfolios can use GPO contracts and enterprise agreements to gain share across multiple GI procedure categories. Clinical differentiation remains important because physicians may resist standardization when a specific device materially affects technical success.

 

By Procedure/Application

Colonoscopy, Colorectal Screening and Polypectomy

Colonoscopy represents the largest procedure-driven application. Demand comes from primary screening, post-polypectomy surveillance, positive non-invasive screening tests, gastrointestinal symptoms, inflammatory bowel disease and post-cancer surveillance. The lowering of routine screening initiation to age 45 expanded the eligible population and created a durable procedural growth opportunity.

Device demand extends well beyond the colonoscope. Each procedure creates potential utilization of biopsy forceps, snares, retrieval devices, clips, injection needles, CO2 insufflation and AI detection technologies. Cases with larger lesions can transition into EMR or other advanced resection workflows, significantly increasing device revenue per procedure.

Upper Gastrointestinal Endoscopy

Upper GI endoscopy is used for dysphagia, reflux-related complications, gastrointestinal bleeding, ulcers, anemia, gastric abnormalities, Barrett’s esophagus, malignancy evaluation and therapeutic treatment. U.S. gastric cancer incidence is materially lower than in several Asian markets, but approximately 31,500 new stomach cancer cases are still expected in 2026. Esophageal cancer adds more than 22,000 expected new cases.

Upper GI endoscopy remains particularly important for hospital-based bleeding evaluation, biopsy, dilation and therapeutic intervention. Large-channel gastroscopes and advanced hemostatic accessories gain value in complex cases.

ERCP and Pancreaticobiliary Intervention

ERCP is one of the highest-value procedure segments despite lower overall volume. More than 500,000 U.S. ERCP procedures are performed annually. The procedure creates demand for duodenoscopes, guidewires, sphincterotomes, extraction balloons, baskets, dilation systems, plastic and metal stents, cholangioscopy and accessories.

ERCP is also where infection-prevention innovation has had its greatest commercial impact. Disposable components and single-use duodenoscopes have created a second procurement pathway alongside reusable platforms.

Endoscopic Ultrasound

EUS is expanding because of rising pancreatic, biliary and subepithelial lesion evaluation. Linear echoendoscopy supports tissue acquisition and intervention, while EUS-guided drainage and therapeutic procedures are expanding the technology’s role beyond diagnosis.

The segment remains concentrated among specialists and high-acuity centers, creating a smaller but premium market with meaningful training barriers. Vendors with integrated EUS processors, echoendoscopes and compatible needles can establish strong physician loyalty.

Advanced Therapeutic Endoscopy

Advanced therapeutic endoscopy includes EMR, ESD, complex hemostasis, luminal stenting, endoscopic closure, endoluminal suturing, bariatric intervention, foreign-body retrieval and selected anti-reflux procedures. Growth is being supported by the ability to treat lesions and structural abnormalities without major surgery.

These procedures generate considerably higher device revenue per case than routine diagnostic endoscopy because multiple specialty accessories may be required. As advanced endoscopist training expands, this segment is expected to contribute disproportionately to market value growth.

 

By Technology

High-Definition and Image-Enhanced Endoscopy

High-definition white-light imaging remains the baseline technology, but premium differentiation increasingly comes from image enhancement. Narrow-band imaging, linked-color imaging, blue-light imaging, texture and color enhancement and bleeding-focused modes are being incorporated into routine endoscopy workflows.

These technologies are particularly important because they can be embedded within the capital platform rather than requiring a separate device for every procedure. This gives manufacturers a mechanism to differentiate processor ecosystems and defend premium pricing.

AI-Assisted Endoscopy

AI-assisted CADe and emerging CADx technologies are among the fastest-growing areas. U.S. adoption is being driven by the pursuit of higher lesion-detection consistency, physician quality improvement and standardization across large gastroenterology groups.

The market is likely to evolve toward subscription, per-procedure and bundled pricing models. Over time, buyers will increasingly demand evidence that AI improves clinically meaningful quality measures rather than merely generating additional visual alerts.

Single-Use and Infection-Prevention Technology

Single-use technology addresses cross-contamination, reprocessing labor, equipment availability and emergency access. Its strongest position remains in complex reusable scopes such as duodenoscopes, but the concept is broadening.

At the same time, reusable fleets are becoming more sophisticated through improved automated endoscope reprocessors, drying and storage systems, inspection technologies, tracking software and standardized cleaning protocols. Consequently, infection prevention is creating growth on both sides of the market rather than driving an immediate universal switch to disposable endoscopy.

Endoscopic Ultrasound and Interventional Imaging

EUS combines endoscopic visualization with ultrasound imaging and increasingly supports therapeutic intervention. Technology competition centers on image quality, needle visualization, maneuverability, compatibility and integration with broader ultrasound architecture.

Advanced centers increasingly want systems that support diagnostic staging, tissue acquisition and therapy rather than a narrowly diagnostic platform. This favors companies able to build procedure ecosystems around the echoendoscope.

Digital Workflow and Quantitative Endoscopy

Digital technologies are becoming an important layer across the GI suite. Lesion measurement, procedure recording, documentation, quality analytics, scope tracking and AI integration can reduce manual work and improve data consistency.

Quantitative lesion-sizing technology is an early example of this transition. As hospitals place greater emphasis on documentation quality and enterprise analytics, software will increasingly influence which physical endoscopy platforms are selected.

 

By End User

Hospitals and Integrated Health Systems

Hospitals represent the largest end-user segment by value because they combine high procedure volumes with advanced ERCP, EUS, emergency bleeding management, inpatient endoscopy and complex therapeutic intervention. Large integrated delivery networks can negotiate enterprise contracts covering capital processors, scope fleets, repair services, endotherapy devices and reprocessing equipment.

Procurement decisions are highly structured. Clinical preference remains influential, but value-analysis committees increasingly examine total ownership cost, repair frequency, service uptime, reprocessing requirements, standardization potential and reimbursement.

Ambulatory Surgery Centers

ASCs are the fastest-growing high-volume channel for routine colonoscopy and upper GI endoscopy. More than 6,400 Medicare-certified ASCs were operating by the end of 2024, and GI procedures are among the sector’s most common services.

ASC operators favor predictable per-case economics. Equipment downtime can directly reduce daily case volume, making service support and scope availability economically significant. Consolidation among gastroenterology practices is also creating larger purchasing organizations with greater negotiating leverage.

Gastroenterology Clinics and Dedicated Endoscopy Centers

Physician-owned and specialty endoscopy centers represent a strategically important channel. They often have highly standardized procedure protocols and significant influence over accessory selection.

These facilities are especially attractive for AI-assisted colonoscopy, outpatient therapeutic procedures and compact visualization systems when the economics can be demonstrated without materially increasing procedure cost.

Academic Medical Centers and Specialty Referral Centers

Academic centers account for a disproportionate share of complex EUS, ERCP, ESD, difficult EMR and clinical trials. They function as early adopters and training hubs for new technologies.

Commercial success in these centers can influence broader market adoption because community physicians often learn advanced procedures through academic programs. However, purchasing decisions tend to require stronger evidence and extensive physician evaluation.

Other Outpatient and Specialized Care Settings

Smaller hospitals, office-based sites, mobile programs and specialized pediatric or esophageal programs constitute a smaller but evolving opportunity. Single-use scopes are particularly relevant where procedure volumes are insufficient to justify a large reusable fleet or full reprocessing infrastructure.

 

Regional Insights: Where the Market Is Growing Fastest

The U.S. Gastrointestinal Endoscopy Devices Market is geographically segmented into the South, West, Northeast and Midwest. Regional performance differs materially according to population size, age structure, colorectal screening penetration, digestive disease prevalence, Medicare exposure, hospital density, ASC concentration, gastroenterologist availability, health-system consolidation and penetration of advanced therapeutic endoscopy.

The South is the largest regional market, representing an estimated USD 2.36 billion in 2025, or approximately 35% of national revenue. The West is expected to record the fastest growth, while the Northeast remains the country’s most concentrated region for academic GI innovation and high-acuity advanced endoscopy. The Midwest provides a large, stable procedure base supported by integrated health systems and established referral centers.

South

The South includes Alabama, Arkansas, Delaware, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia and West Virginia, with the District of Columbia functioning as an additional high-acuity referral market. The region combines rapid population growth, large Medicare populations, high chronic disease burden, expanding suburban healthcare infrastructure and significant ASC development.

The South accounted for an estimated USD 2.36 billion in 2025 and is projected to approach USD 4.91 billion by 2035, implying growth modestly above the national average. The region’s importance is not based on one technology category. It combines high routine colonoscopy volume with significant inpatient bleeding management, ERCP, EUS and growing therapeutic endoscopy capacity.

Texas is the largest individual GI endoscopy market in the region and is modeled at roughly USD 0.55 billion in 2025. Houston, Dallas–Fort Worth, Austin and San Antonio support extensive hospital and gastroenterology networks. Large health systems and private gastroenterology groups create opportunities for enterprise scope standardization, AI-assisted colonoscopy and ASC-focused equipment contracts. Population growth also creates ongoing demand for new procedure rooms rather than replacement capital alone.

Florida is modeled near USD 0.46 billion in 2025 and is one of the country’s most attractive states for GI endoscopy because of its older population, substantial Medicare exposure and large concentration of outpatient procedure centers. The state creates strong demand for colorectal screening, polypectomy, upper GI endoscopy, ERCP and pancreaticobiliary procedures. Manufacturers with strong ASC service models and rapid scope-repair capabilities are particularly well positioned.

North Carolina, Georgia, Tennessee and Virginia are emerging as high-growth state markets. Charlotte, Raleigh-Durham, Atlanta, Nashville, Memphis, Richmond and Northern Virginia support expanding specialty care networks. North Carolina and Tennessee also have strong academic and referral centers that can accelerate adoption of EUS, advanced resection and therapeutic endoscopy.

Maryland and Delaware benefit from dense East Coast referral patterns, high specialist access and proximity to major academic medical systems. Maryland’s Baltimore-Washington corridor supports sophisticated pancreaticobiliary and advanced endoscopy programs. South Carolina is benefiting from population migration and growth in Charleston, Columbia and Greenville, creating additional demand for outpatient endoscopy infrastructure.

Kentucky, Alabama, Mississippi, Louisiana, Arkansas, Oklahoma and West Virginia have smaller absolute markets but clinically important digestive disease and colorectal cancer burdens. Rural access constraints mean a greater share of complicated patients may be referred to metropolitan hubs. These states offer opportunities for scalable outpatient systems, mobile-compatible single-use technologies and equipment platforms that reduce reliance on large reprocessing departments.

The strategic challenge in the South is heterogeneity. Large metropolitan health systems can support premium AI, EUS and advanced therapeutic capital, while rural and community facilities remain highly price sensitive. Manufacturers therefore need differentiated channel strategies rather than a single national contract model.

West

The West includes Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington and Wyoming. The regional market is estimated at approximately USD 1.49 billion in 2025 and could reach about USD 3.25 billion by 2035, making it the fastest-growing U.S. region at an estimated CAGR slightly above 8%.

California is by far the largest Western market and is modeled at approximately USD 0.67 billion in 2025. The state combines enormous population scale with academic medical centers, large integrated health systems, gastroenterology groups, managed-care organizations and a strong digital-health ecosystem. California is particularly important for adoption of AI-assisted colonoscopy, advanced imaging, EUS, ESD and new endoluminal technologies.

Procurement dynamics in California are demanding. Large systems frequently require extensive value analysis, cybersecurity and integration review before adopting new digital platforms. Once approved, however, enterprise deployments across multiple hospitals and outpatient centers can produce substantial commercial scale. The state is therefore attractive to manufacturers with strong clinical evidence and implementation capabilities.

Arizona and Nevada are among the fastest-growing endoscopy markets because of population migration and aging demographics. Phoenix, Scottsdale, Tucson and Las Vegas are expanding specialty-care capacity, driving demand for routine screening as well as advanced GI services. ASC growth is particularly important in these markets.

Washington and Oregon have sophisticated integrated provider systems and strong adoption of digital and value-based care. These states are attractive for technologies that can demonstrate quality improvement, workflow efficiency and longitudinal data capture. Colorado and Utah combine population growth with major regional referral centers and technology-oriented health systems, supporting both capital replacement and greenfield endoscopy expansion.

Idaho, Montana, Wyoming, New Mexico and Alaska have lower absolute procedure volumes and greater geographic access challenges. Single-use technology, regional referral networks and equipment with simplified maintenance can have outsized relevance in these states. Hawaii has a relatively small market but benefits from concentrated hospital demand and an aging population.

The West’s strategic advantage is innovation readiness. New imaging modalities, AI, quantitative endoscopy and digital workflow tools often gain early traction in large Western health systems. Its limitation is fragmentation: large distances and smaller rural markets increase service requirements for manufacturers. Companies able to combine sophisticated technology with reliable field support are likely to gain share.

Northeast

The Northeast includes Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island and Vermont. The region represented an estimated USD 1.55 billion in 2025 and is projected to reach approximately USD 3.05 billion by 2035.

The Northeast is one of the highest-value regions per procedure because of its concentration of academic hospitals, advanced therapeutic endoscopists, oncology centers and pancreaticobiliary programs. It is often the first U.S. region where novel devices are evaluated in complex clinical settings, making it disproportionately important for product launches even when absolute population growth is slower than in the South or West.

New York is the largest Northeast state market and is modeled around USD 0.44 billion in 2025. New York City has one of the country’s densest concentrations of tertiary GI programs, while suburban health systems and upstate regional networks create substantial routine colonoscopy volume. The market supports premium visualization, EUS, complex ERCP, advanced polypectomy and therapeutic endoscopy.

Pennsylvania represents another major market, with large provider systems in Philadelphia, Pittsburgh and surrounding communities. New Jersey has strong outpatient penetration and benefits from close referral integration with New York and Philadelphia. Both states are important for large gastroenterology groups and ASC purchasing.

Massachusetts is smaller by population but has exceptional strategic influence. Boston’s academic centers participate heavily in clinical research, physician education and evaluation of advanced endoscopy technology. Adoption within these institutions can affect purchasing preferences far beyond the state.

Connecticut and Rhode Island provide dense, relatively high-value healthcare markets with strong specialist access. Maine, New Hampshire and Vermont have smaller populations and more rural care requirements, creating demand for regional hub models and outpatient efficiency. These states may be attractive for technologies that reduce equipment complexity or enable procedures closer to the patient.

The Northeast is likely to grow somewhat more slowly than the West and South because population growth is limited and many hospitals already have mature endoscopy infrastructure. Nevertheless, replacement cycles for processors and scope fleets, AI adoption and expansion of advanced therapy should keep market value growth healthy.

Midwest

The Midwest includes Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota and Wisconsin. The region accounted for approximately USD 1.35 billion in 2025 and could reach approximately USD 2.63 billion by 2035.

The Midwest provides a durable base of hospital and outpatient procedure demand. The region has major integrated delivery networks, academic centers and community hospitals, but generally experiences slower population growth than the South and West. As a result, replacement capital, service quality and procedure economics play a larger role than greenfield facility expansion.

Illinois is the largest Midwest market, supported by Chicago’s academic centers, large community networks and suburban endoscopy facilities. The state is modeled around USD 0.24 billion in 2025. Ohio follows closely because Cleveland, Columbus and Cincinnati have substantial specialty-care capacity and nationally recognized referral centers.

Michigan has a sizable procedure base across Detroit, Ann Arbor and regional systems, while Minnesota is strategically important because of its medtech ecosystem, large integrated providers and strong culture of technology evaluation. These states are attractive for AI, endoscopic ultrasound and advanced therapy adoption.

Indiana, Wisconsin and Missouri provide large community GI markets with strong hospital and ASC activity. Indianapolis, Milwaukee, Madison, St. Louis and Kansas City function as important referral hubs. Iowa, Kansas and Nebraska have smaller populations but stable endoscopy demand and well-developed regional health systems.

North Dakota and South Dakota are the smallest state markets in the region. Geographic dispersion increases the importance of referral centers, equipment reliability and service responsiveness. Portable or single-use solutions can have a stronger value proposition where maintaining large scope fleets or specialized reprocessing resources is inefficient.

The Midwest is unlikely to lead national growth, but it remains commercially attractive because of predictable procedure volumes, mature purchasing organizations and a sizable installed base requiring ongoing replacement. Manufacturers that can demonstrate durable equipment, strong service and cost-efficient contracting can defend market share effectively.

 

Key Market Players

The U.S. Gastrointestinal Endoscopy Devices Competitive Landscape is concentrated around several global medtech companies in core scope and processor systems, while the broader endotherapy ecosystem remains highly fragmented. Olympus, Boston Scientific, Fujifilm, PENTAX Medical and Medtronic hold particularly influential positions because they participate in major parts of the procedural pathway rather than one accessory category.

Competition is moving toward platform economics. Visualization vendors seek to control the installed base of processors and scopes; therapeutic companies seek to expand procedure-specific consumables; AI companies seek integration into existing workflows; and single-use manufacturers seek to alter the economics of reusable equipment. GPO contracting, physician preference, installed-base lock-in, service quality, FDA clearances, evidence generation and clinician training will determine share movement through 2035.

Some of the key players in the U.S. Gastrointestinal Endoscopy Devices industry are:

Olympus Corporation
Boston Scientific Corporation
FUJIFILM Healthcare Americas Corporation
PENTAX Medical / HOYA Corporation
Medtronic
STERIS
Ambu A/S
CONMED Corporation
Cook Medical
Micro-Tech Endoscopy USA
Merit Medical Systems
ERBE USA
Ovesco Endoscopy USA
Creo Medical
EndoGastric Solutions
CapsoVision
AnX Robotica
KARL STORZ Endoscopy-America
Richard Wolf Medical Instruments
Cosmo Intelligent Medical Devices / Cosmo Pharmaceuticals
EvoEndo
CDx Diagnostics
EndoSound

Olympus remains one of the most influential companies in reusable GI endoscopy because of its large installed base, visualization ecosystem and endotherapy presence. Its EVIS X1 platform represents the industry’s transition toward multi-modal image enhancement. Boston Scientific has built one of the broadest therapeutic endoscopy portfolios, with strength across ERCP, biliary intervention, EUS-guided devices, hemostasis, stents, single-use duodenoscopy and advanced intervention.

Fujifilm is strengthening its U.S. position through ELUXEO imaging, CAD EYE artificial intelligence and quantitative lesion-measurement technology. PENTAX Medical competes through imaging, scope ergonomics and processor technology, while Medtronic has an important position in AI-assisted colonoscopy and capsule endoscopy.

STERIS has a differentiated position because it participates in both endotherapy accessories and endoscope reprocessing. Ambu is strategically significant in single-use flexible endoscopy, while Cook Medical, CONMED, Micro-Tech Endoscopy, Merit Medical, ERBE and Ovesco compete across high-value therapeutic categories.

Specialized companies will remain important because advanced endoscopy does not always reward portfolio breadth. Innovations in closure, ablation, suturing, AI, capsule imaging, transnasal endoscopy and therapeutic ultrasound can allow smaller companies to penetrate major health systems when they provide clear clinical differentiation.

 

Recent Developments

Recent developments in the U.S. gastrointestinal endoscopy devices market indicate that competitive intensity is shifting toward AI, advanced visualization, ergonomics, infection prevention and quantitative procedural data.

In 2024, Fujifilm received U.S. FDA 510(k) clearance for CAD EYE, its AI-based system for real-time detection of colonic mucosal lesions. The development is strategically significant because it brings AI directly into a major endoscopy manufacturer’s imaging ecosystem rather than requiring a standalone third-party workflow. Fujifilm also received 510(k) clearance in 2024 for SCALE EYE, which provides virtual measurement of colorectal lesions and supports more standardized assessment of polyp size.

Medtronic’s GI Genius ecosystem continued to evolve through FDA clearances covering updated module and ColonPRO configurations during 2024. The significance of these developments is broader than one product. AI is moving toward an expected capability within premium colonoscopy rather than remaining a separate experimental category.

PENTAX Medical received FDA clearance in December 2024 for additional i20c Video Endoscope Series models, including a slim colonoscope and upper GI scope. The systems emphasize advanced imaging, maneuverability and ergonomics, reflecting the increasing importance of physician fatigue and handling performance in high-volume endoscopy environments.

Olympus’ U.S. launch of EVIS X1 established a major replacement cycle in advanced GI visualization. The platform combines conventional endoscopic imaging with technologies designed to enhance mucosal texture, color, vascular visualization and bleeding recognition. Large installed-base transitions such as this can influence capital purchasing for several years because processor upgrades drive subsequent scope replacement decisions.

Single-use duodenoscopy continues to mature. FDA guidance has encouraged U.S. facilities to move away from older fixed-endcap duodenoscope designs toward modern designs that facilitate or eliminate reprocessing. Boston Scientific’s EXALT platform and Ambu’s disposable duodenoscope portfolio represent the competitive direction toward patient-ready, sterile ERCP scopes for selected use cases. The largest commercial opportunity may ultimately be hybrid rather than universal conversion, with hospitals maintaining reusable fleets while using single-use devices for high-risk patients, emergency availability and operational contingencies.

Reimbursement policy is also influencing demand. Effective in 2025, Medicare expanded its definition of complete colorectal cancer screening to include follow-on colonoscopy after a positive covered blood-based biomarker screening test. This policy reinforces the role of colonoscopy as the definitive diagnostic and therapeutic endpoint even as non-invasive screening technologies expand.

Clinical demand indicators remain strong entering the forecast period. Approximately 158,850 colorectal cancer cases are expected in the United States in 2026, and the disease burden is shifting toward younger adults. At the same time, the latest national data indicate approximately 4.1 million U.S. adults have been diagnosed with inflammatory bowel disease. These trends reinforce the long-term requirement for both preventive and disease-surveillance endoscopy.

 

Conclusion

The U.S. Gastrointestinal Endoscopy Devices Market Size & Share is positioned to increase from approximately USD 6.75 billion in 2025 to USD 13.81 billion by 2035, representing a modeled CAGR of 7.42% during 2026–2035. The opportunity is being driven by an expanding colorectal screening population, persistent screening gaps, rising chronic GI disease burden, outpatient procedure migration, advanced therapeutic endoscopy, AI-assisted visualization, infection-prevention requirements and increasing device value per procedure.

The strongest growth will not come from routine scope replacement alone. AI-assisted colonoscopy, premium image enhancement, single-use scopes, EUS-guided intervention, advanced polypectomy, endoscopic resection, hemostasis, GI stenting, endoluminal closure and digital workflow solutions are expected to generate disproportionate value expansion. Routine colonoscopy and upper GI endoscopy will remain the volume foundation, but complex therapy will increasingly shape competitive differentiation.

The South will remain the largest regional market through 2035 because of Texas and Florida’s scale, rapid population growth and expanding ambulatory infrastructure. The West is expected to grow fastest, led by California, Arizona, Nevada, Washington, Colorado and Utah. The Northeast will retain outsized influence in clinical innovation because of New York, Massachusetts, Pennsylvania and New Jersey, while the Midwest will remain a stable installed-base and replacement market centered on Illinois, Ohio, Michigan, Minnesota, Wisconsin, Indiana and Missouri.

For manufacturers and investors, the most important strategic issue is no longer whether U.S. GI endoscopy volumes will remain substantial. The critical question is how much value will migrate from traditional reusable optics toward integrated visualization, AI, advanced therapy, single-use technology and procedure-level consumables.

For hospitals and gastroenterology groups, procurement decisions will increasingly be based on total endoscopy-suite economics: scope uptime, repair burden, reprocessing capacity, physician efficiency, procedure duration, accessory standardization, infection prevention, diagnostic quality and reimbursement capture. Companies able to improve these economics while maintaining physician confidence will be best positioned to defend premium pricing.

For new entrants, the market remains accessible despite strong incumbents, but differentiation must be clinically meaningful. A new device that simply adds another accessory to a crowded category will face intense contracting pressure. Technologies that enable procedures previously requiring surgery, improve detection, eliminate workflow bottlenecks, reduce reprocessing complexity or measurably improve procedural consistency have a more credible path to adoption.

Between 2026 and 2035, the U.S. gastrointestinal endoscopy devices market will increasingly function as a connected procedural ecosystem rather than a collection of scopes and accessories. The companies that control the clinical workflow—from visualization and detection through tissue acquisition, therapy, documentation and post-procedure quality analysis—are likely to capture the greatest share of the market’s next growth cycle.

 

TABLE OF CONTENT

1. U.S. Gastrointestinal Endoscopy Devices Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Market Sizing, Triangulation & Forecasting Models
1.3.6. Procedure-Volume and Installed-Base Modeling
1.3.7. Data Validation and Final Report Publishing
1.4. Key Assumptions
1.4.1. Historical Period, 2021–2024
1.4.2. Base Year, 2025
1.4.3. Forecast Period, 2026–2035
1.4.4. Currency and Market Valuation – US$ Billion
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. Gastrointestinal Endoscope Manufacturers
1.6.2. Visualization and Imaging System Manufacturers
1.6.3. Endotherapy Device and Accessory Manufacturers
1.6.4. Endoscope Reprocessing and Infection-Prevention Providers
1.6.5. Hospitals and Integrated Delivery Networks
1.6.6. Ambulatory Surgery Centers
1.6.7. Gastroenterology Practices and Dedicated Endoscopy Centers
1.6.8. Academic Medical Centers and Advanced Endoscopy Referral Centers
1.6.9. Group Purchasing Organizations and Specialty Distributors
1.6.10. Payers, CMS, FDA and Clinical Decision-Makers

What this section provides: This section defines the U.S. gastrointestinal endoscopy devices market boundary, study scope, methodology, assumptions, device ecosystem and stakeholder structure, allowing clients to understand how market revenues, procedure demand and forecasts are measured and validated.

2. U.S. Gastrointestinal Endoscopy Devices Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. Market Size & Growth Trajectory, 2021–2035
2.8. High-Growth Opportunity Areas
2.8.1. AI-Assisted Colonoscopy
2.8.2. Advanced Therapeutic Endoscopy
2.8.3. Single-Use Gastrointestinal Endoscopes
2.8.4. Endoscopic Ultrasound-Guided Intervention
2.8.5. ERCP and Pancreaticobiliary Devices
2.8.6. Advanced Endotherapy Consumables
2.8.7. ASC-Based Gastrointestinal Endoscopy
2.9. Key Market Risks and Watchpoints

What this section provides: This section gives executives a concise view of the U.S. gastrointestinal endoscopy devices market size, historical development, 2025 positioning, forecast growth through 2035, major demand pools, high-growth technologies and priority commercial opportunities.

3. U.S. Gastrointestinal Endoscopy Devices Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. Expanding Colorectal Cancer Screening Population
3.1.2. Large Unscreened and Underscreened U.S. Adult Population
3.1.3. Rising Burden of Colorectal, Gastric, Esophageal and Pancreatic Diseases
3.1.4. Increasing Prevalence of Inflammatory Bowel Disease
3.1.5. Growth in Colonoscopy and Upper GI Endoscopy Procedures
3.1.6. Expansion of ERCP and Pancreaticobiliary Intervention
3.1.7. Increasing Adoption of Endoscopic Ultrasound
3.1.8. Shift from Diagnostic to Therapeutic Endoscopy
3.1.9. Growth of Ambulatory Gastrointestinal Endoscopy
3.1.10. AI-Assisted Polyp Detection and Digital Endoscopy Adoption
3.1.11. Hospital Endoscopy Suite Modernization and Replacement Cycles
3.1.12. Expanding Medicare Screening and Follow-On Colonoscopy Coverage
3.2. Restraints and Their Impact Analysis
3.2.1. High Capital Cost of Premium Endoscopy Platforms
3.2.2. High Scope Repair and Maintenance Costs
3.2.3. Endoscope Reprocessing Complexity and Labor Burden
3.2.4. Gastroenterologist and Advanced Endoscopist Workforce Constraints
3.2.5. Reimbursement Pressure in High-Volume Outpatient Procedures
3.2.6. Hospital Value Analysis and Capital Budget Scrutiny
3.2.7. Sustainability Concerns Around Disposable Endoscopy Products
3.2.8. Product Recall, Infection and Device Safety Risks
3.3. Opportunities and Their Impact Analysis
3.3.1. AI-Enabled Computer-Aided Detection and Diagnosis
3.3.2. Advanced Endoscopic Mucosal Resection and Submucosal Dissection
3.3.3. Single-Use Duodenoscope and Gastroscope Adoption
3.3.4. EUS-Guided Therapeutic Procedures
3.3.5. Advanced Hemostasis and Endoscopic Closure
3.3.6. Digital Lesion Measurement and Quantitative Endoscopy
3.3.7. Endoscopic Bariatric and Metabolic Procedures
3.3.8. Outpatient and ASC Expansion
3.3.9. Integrated Capital-Consumable Contracting Models
3.3.10. Underserved Rural and Community Endoscopy Markets
3.4. Challenges and Their Impact Analysis
3.4.1. Balancing Clinical Innovation with Procedure-Level Economics
3.4.2. Reusable Versus Single-Use Cost Trade-Offs
3.4.3. Physician Preference and Platform Switching Barriers
3.4.4. Endoscope Reprocessing Compliance
3.4.5. Interoperability and AI Workflow Integration
3.5. Patent & Innovation Analysis, 2021–2025
3.6. Gastrointestinal Endoscopy Procedure Volume Analysis
3.7. Clinical Workflow Economics Analysis
3.8. Hospital and ASC Capital Procurement Behavior Analysis
3.9. Installed-Base Replacement Cycle Analysis

What this section provides: This section explains the clinical, economic, reimbursement, operational and technology forces shaping U.S. gastrointestinal endoscopy device demand and helps clients evaluate both growth opportunities and commercialization risks.

4. U.S. Gastrointestinal Endoscopy Devices Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Threat of Substitute Technologies
4.2.5. Competitive Rivalry
4.3. Pricing Trend Analysis by Region, 2025–2035
4.4. Value Chain & Supply Chain Analysis
4.4.1. Optical and Imaging Components
4.4.2. Scope and Processor Manufacturing
4.4.3. Disposable Endotherapy Manufacturing
4.4.4. Distribution and GPO Channels
4.4.5. Hospital and ASC Procurement
4.4.6. Reprocessing, Repair and Aftermarket Services
4.5. Impact of Digitalization and Connected Endoscopy
4.6. Clinical Application & Innovation Landscape
4.7. FDA Regulatory Framework Analysis
4.7.1. Gastrointestinal Endoscope Regulatory Pathways
4.7.2. Endotherapy Device Regulation
4.7.3. AI/Software-Enabled Endoscopy Regulation
4.7.4. Single-Use Endoscope Regulatory Considerations
4.7.5. Post-Market Surveillance and Recall Environment
4.8. CMS Reimbursement and Coverage Landscape
4.8.1. Screening Colonoscopy
4.8.2. Diagnostic Colonoscopy
4.8.3. Upper GI Endoscopy
4.8.4. ERCP
4.8.5. EUS
4.8.6. Advanced Therapeutic Endoscopy
4.8.7. Hospital Outpatient Versus ASC Payment Dynamics
4.9. Import/Export Restrictions & Tariff Impact
4.10. Government Colorectal Cancer Screening Initiatives
4.11. Impact of Escalating Geopolitical and Supply-Chain Tensions
4.12. Hospital Value Analysis Committee Decision Framework
4.13. Sustainability and Medical Waste Considerations

What this section provides: This section gives clients a complete view of the regulatory, reimbursement, technology, pricing, supply-chain, sustainability and procurement environment affecting the U.S. gastrointestinal endoscopy devices industry.

5. U.S. Gastrointestinal Endoscopy Devices Market – By Product Type

5.1. Overview
5.1.1. Segment Share Analysis, By Product Type, 2025 & 2035 (%)
5.1.2. Reusable Flexible Gastrointestinal Endoscopes
5.1.2.1. Colonoscopes
5.1.2.2. Gastroscopes
5.1.2.3. Duodenoscopes
5.1.2.4. Enteroscopes
5.1.2.5. Sigmoidoscopes
5.1.2.6. Other Reusable GI Endoscopes
5.1.3. Single-Use Gastrointestinal Endoscopes
5.1.3.1. Single-Use Duodenoscopes
5.1.3.2. Single-Use Gastroscopes
5.1.3.3. Single-Use Colonoscopy Platforms
5.1.3.4. Other Single-Use GI Endoscopes
5.1.4. Visualization and Imaging Systems
5.1.4.1. Video Processors
5.1.4.2. Light Sources
5.1.4.3. High-Definition Visualization Systems
5.1.4.4. Endoscopic Monitors and Displays
5.1.4.5. Image-Enhancement Platforms
5.1.5. Endoscopic Ultrasound and Capsule Endoscopy Systems
5.1.5.1. Linear Echoendoscopes
5.1.5.2. Radial Echoendoscopes
5.1.5.3. EUS Processors and Ultrasound Platforms
5.1.5.4. Capsule Endoscopy Systems
5.1.5.5. Capsule Reading and Interpretation Platforms
5.1.6. Endotherapy Devices and Accessories
5.1.6.1. Biopsy Forceps and Tissue Sampling Devices
5.1.6.2. Polypectomy Snares
5.1.6.3. Retrieval Devices
5.1.6.4. Injection Needles
5.1.6.5. Guidewires
5.1.6.6. Dilation Balloons and Dilators
5.1.6.7. Hemostasis Clips and Devices
5.1.6.8. Biliary and Enteral Stents
5.1.6.9. Sphincterotomes
5.1.6.10. Stone Extraction Balloons and Baskets
5.1.6.11. EUS-Guided Tissue Acquisition Needles
5.1.6.12. Endoscopic Closure and Suturing Devices
5.1.6.13. Ablation Devices
5.1.6.14. Other Endotherapy Accessories

What this section provides: This section identifies the gastrointestinal endoscopy product categories generating the largest revenue pools, recurring consumable demand and strongest growth potential through 2035.

6. U.S. Gastrointestinal Endoscopy Devices Market – By Procedure/Application

6.1. Overview
6.1.1. Segment Share Analysis, By Procedure/Application, 2025 & 2035 (%)
6.1.2. Colonoscopy, Colorectal Cancer Screening & Polypectomy
6.1.2.1. Screening Colonoscopy
6.1.2.2. Surveillance Colonoscopy
6.1.2.3. Diagnostic Colonoscopy
6.1.2.4. Polypectomy
6.1.2.5. Endoscopic Mucosal Resection
6.1.3. Upper Gastrointestinal Endoscopy
6.1.3.1. Diagnostic Esophagogastroduodenoscopy
6.1.3.2. Gastrointestinal Bleeding Management
6.1.3.3. Barrett’s Esophagus Surveillance
6.1.3.4. Esophageal and Gastric Biopsy
6.1.3.5. Stricture Dilation and Stenting
6.1.4. ERCP and Pancreaticobiliary Intervention
6.1.4.1. Biliary Stone Management
6.1.4.2. Biliary Stricture Management
6.1.4.3. Pancreatic Duct Intervention
6.1.4.4. Biliary and Pancreatic Stenting
6.1.4.5. Cholangioscopy-Assisted Procedures
6.1.5. Endoscopic Ultrasound
6.1.5.1. Diagnostic EUS
6.1.5.2. EUS-Guided Fine Needle Aspiration
6.1.5.3. EUS-Guided Fine Needle Biopsy
6.1.5.4. EUS-Guided Drainage
6.1.5.5. EUS-Guided Therapeutic Intervention
6.1.6. Advanced Therapeutic Endoscopy
6.1.6.1. Endoscopic Mucosal Resection
6.1.6.2. Endoscopic Submucosal Dissection
6.1.6.3. Advanced Hemostasis
6.1.6.4. Endoscopic Closure and Suturing
6.1.6.5. Endoluminal Stenting
6.1.6.6. Endoscopic Bariatric Procedures
6.1.6.7. Foreign-Body Retrieval
6.1.6.8. Other Advanced Endoscopic Procedures

What this section provides: This section evaluates gastrointestinal endoscopy demand by procedure and clinical use case, allowing clients to identify applications with high procedure volumes, premium device utilization and favorable long-term growth.

7. U.S. Gastrointestinal Endoscopy Devices Market – By Technology

7.1. Overview
7.1.1. Segment Share Analysis, By Technology, 2025 & 2035 (%)
7.1.2. High-Definition and Image-Enhanced Endoscopy
7.1.2.1. High-Definition White-Light Imaging
7.1.2.2. Narrow-Band Imaging
7.1.2.3. Linked-Color Imaging
7.1.2.4. Blue-Light Imaging
7.1.2.5. Texture and Color Enhancement
7.1.2.6. Bleeding Visualization Technologies
7.1.3. AI-Assisted Endoscopy
7.1.3.1. Computer-Aided Detection
7.1.3.2. Computer-Aided Diagnosis
7.1.3.3. AI-Assisted Polyp Characterization
7.1.3.4. AI-Assisted Procedure Quality Analytics
7.1.3.5. AI-Enabled Capsule Endoscopy Interpretation
7.1.4. Single-Use and Infection-Prevention Technology
7.1.4.1. Fully Disposable Endoscopes
7.1.4.2. Disposable Endoscope Components
7.1.4.3. Automated Endoscope Reprocessors
7.1.4.4. Drying and Storage Technologies
7.1.4.5. Scope Tracking and Reprocessing Verification
7.1.5. Endoscopic Ultrasound and Interventional Imaging
7.1.5.1. Radial EUS
7.1.5.2. Linear EUS
7.1.5.3. Doppler-Enhanced EUS
7.1.5.4. EUS-Guided Interventional Technologies
7.1.6. Digital Workflow and Quantitative Endoscopy
7.1.6.1. Digital Lesion Measurement
7.1.6.2. Procedure Documentation Systems
7.1.6.3. Image and Video Management
7.1.6.4. Quality Analytics Platforms
7.1.6.5. Endoscopy Data Integration

What this section provides: This section evaluates the technology platforms reshaping U.S. gastrointestinal endoscopy, with emphasis on premium imaging, AI, infection prevention, EUS and software-enabled procedure workflows.

8. U.S. Gastrointestinal Endoscopy Devices Market – By End User

8.1. Overview
8.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)
8.1.2. Hospitals and Integrated Health Systems
8.1.2.1. Large Academic and Tertiary Hospitals
8.1.2.2. Community Hospitals
8.1.2.3. Integrated Delivery Networks
8.1.3. Ambulatory Surgery Centers
8.1.3.1. Independent ASCs
8.1.3.2. Hospital-Affiliated ASCs
8.1.3.3. Gastroenterology Group-Owned ASCs
8.1.4. Gastroenterology Clinics and Dedicated Endoscopy Centers
8.1.5. Academic Medical Centers and Advanced Endoscopy Referral Centers
8.1.6. Other Outpatient and Specialized Care Settings
8.1.6.1. Rural and Community Procedure Centers
8.1.6.2. Pediatric Gastroenterology Centers
8.1.6.3. Mobile and Specialty Endoscopy Settings

What this section provides: This section explains which U.S. care settings generate gastrointestinal endoscopy equipment and consumable demand, with specific emphasis on the migration of routine procedures toward ambulatory settings and concentration of advanced endoscopy within tertiary centers.

9. U.S. Gastrointestinal Endoscopy Devices Market: Clinical Workflow, Procedure Economics & Procurement Intelligence

9.1. Overview
9.2. U.S. Gastrointestinal Endoscopy Clinical Workflow Analysis
9.2.1. Patient Referral and Screening
9.2.2. Pre-Procedure Workflow
9.2.3. Procedure-Room Workflow
9.2.4. Post-Procedure Recovery and Documentation
9.2.5. Endoscope Reprocessing Workflow
9.3. Procedure-Level Cost Analysis
9.3.1. Colonoscopy
9.3.2. Upper GI Endoscopy
9.3.3. ERCP
9.3.4. EUS
9.3.5. Advanced Therapeutic Endoscopy
9.4. Reusable Versus Single-Use Endoscope Economics
9.5. Endoscope Reprocessing Cost and Capacity Analysis
9.6. Scope Repair, Maintenance and Service Contract Economics
9.7. Capital Equipment Replacement Cycle Analysis
9.8. Hospital and IDN Procurement Behavior
9.9. GPO Contracting and Vendor Standardization
9.10. ASC Procurement Economics
9.11. Physician Preference and Clinical Evaluation Influence
9.12. Value Analysis Committee Decision Framework
9.13. Capital Equipment Bundling and Consumable Pull-Through
9.14. Site-of-Care Reimbursement Economics
9.15. Total Cost of Ownership Framework
9.16. Procurement Implications for Market Participants

What this section provides: This section converts device demand into real U.S. provider economics by analyzing procedure costs, capital replacement, reprocessing, repair burden, physician influence, GPO contracting, ASC economics and total cost of ownership.

10. U.S. Gastrointestinal Endoscopy Devices Market – By Geography

10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
10.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
10.1.3. Regional Gastrointestinal Endoscopy Procedure Volume Analysis
10.1.4. Regional Hospital, ASC and Gastroenterology Infrastructure Analysis
10.1.5. Regional Colorectal Cancer Screening and Disease-Burden Analysis
10.1.6. Regional Reimbursement, Procurement and Technology Adoption Dynamics
10.2. West Region
10.2.1. Regional Overview & Trends
10.2.2. West Region GI Endoscopy Key Manufacturers and Procurement Ecosystem
10.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.2.4. West Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.5. West Region Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.2.6. West Region Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.7. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.8. West Region Procedure Economics and Procurement Dynamics
10.2.9. California
10.2.9.1. Overview
10.2.9.2. California Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.9.3. California Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.2.9.4. California Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.9.5. California Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.9.6. California Procedure Volume, ASC and Procurement Dynamics
10.2.10. Washington
10.2.10.1. Overview
10.2.10.2. Washington Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.10.3. Washington Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.2.10.4. Washington Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.10.5. Washington Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.10.6. Washington Procedure Volume, ASC and Procurement Dynamics
10.2.11. Arizona
10.2.11.1. Overview
10.2.11.2. Arizona Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.11.3. Arizona Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.2.11.4. Arizona Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.11.5. Arizona Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.11.6. Arizona Procedure Volume, ASC and Procurement Dynamics
10.2.12. Colorado
10.2.12.1. Overview
10.2.12.2. Colorado Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.12.3. Colorado Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.2.12.4. Colorado Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.12.5. Colorado Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.12.6. Colorado Procedure Volume, ASC and Procurement Dynamics
10.2.13. Oregon
10.2.13.1. Overview
10.2.13.2. Oregon Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.13.3. Oregon Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.2.13.4. Oregon Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.13.5. Oregon Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.13.6. Oregon Procedure Volume, ASC and Procurement Dynamics
10.2.14. Utah
10.2.14.1. Overview
10.2.14.2. Utah Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.14.3. Utah Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.2.14.4. Utah Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.14.5. Utah Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.14.6. Utah Procedure Volume, ASC and Procurement Dynamics
10.2.15. Nevada
10.2.15.1. Overview
10.2.15.2. Nevada Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.15.3. Nevada Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.2.15.4. Nevada Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.15.5. Nevada Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.15.6. Nevada Procedure Volume, ASC and Procurement Dynamics
10.2.16. New Mexico
10.2.16.1. Overview
10.2.16.2. New Mexico Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.16.3. New Mexico Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.2.16.4. New Mexico Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.16.5. New Mexico Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.16.6. New Mexico Procedure Volume, ASC and Procurement Dynamics
10.2.17. Idaho
10.2.17.1. Overview
10.2.17.2. Idaho Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.17.3. Idaho Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.2.17.4. Idaho Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.17.5. Idaho Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.17.6. Idaho Procedure Volume, ASC and Procurement Dynamics
10.2.18. Montana
10.2.18.1. Overview
10.2.18.2. Montana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.18.3. Montana Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.2.18.4. Montana Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.18.5. Montana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.18.6. Montana Procedure Volume, ASC and Procurement Dynamics
10.2.19. Wyoming
10.2.19.1. Overview
10.2.19.2. Wyoming Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.19.3. Wyoming Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.2.19.4. Wyoming Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.19.5. Wyoming Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.19.6. Wyoming Procedure Volume, ASC and Procurement Dynamics
10.2.20. Alaska
10.2.20.1. Overview
10.2.20.2. Alaska Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.20.3. Alaska Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.2.20.4. Alaska Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.20.5. Alaska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.20.6. Alaska Procedure Volume, ASC and Procurement Dynamics
10.2.21. Hawaii
10.2.21.1. Overview
10.2.21.2. Hawaii Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.21.3. Hawaii Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.2.21.4. Hawaii Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.21.5. Hawaii Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.21.6. Hawaii Procedure Volume, ASC and Procurement Dynamics
10.3. Northeast Region
10.3.1. Regional Overview & Trends
10.3.2. Northeast Region GI Endoscopy Key Manufacturers and Procurement Ecosystem
10.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.3.4. Northeast Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.5. Northeast Region Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.3.6. Northeast Region Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.7. Northeast Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.8. Northeast Region Procedure Economics and Procurement Dynamics
10.3.9. New York
10.3.9.1. Overview
10.3.9.2. New York Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.9.3. New York Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.3.9.4. New York Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.9.5. New York Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.9.6. New York Procedure Volume, ASC and Procurement Dynamics
10.3.10. Massachusetts
10.3.10.1. Overview
10.3.10.2. Massachusetts Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.10.3. Massachusetts Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.3.10.4. Massachusetts Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.10.5. Massachusetts Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.10.6. Massachusetts Procedure Volume, ASC and Procurement Dynamics
10.3.11. New Jersey
10.3.11.1. Overview
10.3.11.2. New Jersey Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.11.3. New Jersey Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.3.11.4. New Jersey Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.11.5. New Jersey Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.11.6. New Jersey Procedure Volume, ASC and Procurement Dynamics
10.3.12. Pennsylvania
10.3.12.1. Overview
10.3.12.2. Pennsylvania Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.12.3. Pennsylvania Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.3.12.4. Pennsylvania Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.12.5. Pennsylvania Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.12.6. Pennsylvania Procedure Volume, ASC and Procurement Dynamics
10.3.13. Connecticut
10.3.13.1. Overview
10.3.13.2. Connecticut Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.13.3. Connecticut Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.3.13.4. Connecticut Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.13.5. Connecticut Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.13.6. Connecticut Procedure Volume, ASC and Procurement Dynamics
10.3.14. Maine
10.3.14.1. Overview
10.3.14.2. Maine Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.14.3. Maine Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.3.14.4. Maine Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.14.5. Maine Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.14.6. Maine Procedure Volume, ASC and Procurement Dynamics
10.3.15. Vermont
10.3.15.1. Overview
10.3.15.2. Vermont Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.15.3. Vermont Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.3.15.4. Vermont Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.15.5. Vermont Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.15.6. Vermont Procedure Volume, ASC and Procurement Dynamics
10.3.16. New Hampshire
10.3.16.1. Overview
10.3.16.2. New Hampshire Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.16.3. New Hampshire Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.3.16.4. New Hampshire Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.16.5. New Hampshire Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.16.6. New Hampshire Procedure Volume, ASC and Procurement Dynamics
10.3.17. Rhode Island
10.3.17.1. Overview
10.3.17.2. Rhode Island Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.17.3. Rhode Island Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.3.17.4. Rhode Island Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.17.5. Rhode Island Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.17.6. Rhode Island Procedure Volume, ASC and Procurement Dynamics
10.4. South Region
10.4.1. Regional Overview & Trends
10.4.2. South Region GI Endoscopy Key Manufacturers and Procurement Ecosystem
10.4.3. South Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.4.4. South Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.5. South Region Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.4.6. South Region Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.7. South Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.8. South Region Procedure Economics and Procurement Dynamics
10.4.9. Texas
10.4.9.1. Overview
10.4.9.2. Texas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.9.3. Texas Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.4.9.4. Texas Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.9.5. Texas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.9.6. Texas Procedure Volume, ASC and Procurement Dynamics
10.4.10. Florida
10.4.10.1. Overview
10.4.10.2. Florida Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.10.3. Florida Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.4.10.4. Florida Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.10.5. Florida Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.10.6. Florida Procedure Volume, ASC and Procurement Dynamics
10.4.11. Georgia
10.4.11.1. Overview
10.4.11.2. Georgia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.11.3. Georgia Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.4.11.4. Georgia Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.11.5. Georgia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.11.6. Georgia Procedure Volume, ASC and Procurement Dynamics
10.4.12. North Carolina
10.4.12.1. Overview
10.4.12.2. North Carolina Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.12.3. North Carolina Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.4.12.4. North Carolina Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.12.5. North Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.12.6. North Carolina Procedure Volume, ASC and Procurement Dynamics
10.4.13. Tennessee
10.4.13.1. Overview
10.4.13.2. Tennessee Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.13.3. Tennessee Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.4.13.4. Tennessee Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.13.5. Tennessee Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.13.6. Tennessee Procedure Volume, ASC and Procurement Dynamics
10.4.14. South Carolina
10.4.14.1. Overview
10.4.14.2. South Carolina Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.14.3. South Carolina Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.4.14.4. South Carolina Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.14.5. South Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.14.6. South Carolina Procedure Volume, ASC and Procurement Dynamics
10.4.15. Alabama
10.4.15.1. Overview
10.4.15.2. Alabama Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.15.3. Alabama Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.4.15.4. Alabama Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.15.5. Alabama Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.15.6. Alabama Procedure Volume, ASC and Procurement Dynamics
10.4.16. Mississippi
10.4.16.1. Overview
10.4.16.2. Mississippi Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.16.3. Mississippi Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.4.16.4. Mississippi Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.16.5. Mississippi Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.16.6. Mississippi Procedure Volume, ASC and Procurement Dynamics
10.4.17. Louisiana
10.4.17.1. Overview
10.4.17.2. Louisiana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.17.3. Louisiana Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.4.17.4. Louisiana Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.17.5. Louisiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.17.6. Louisiana Procedure Volume, ASC and Procurement Dynamics
10.4.18. Arkansas
10.4.18.1. Overview
10.4.18.2. Arkansas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.18.3. Arkansas Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.4.18.4. Arkansas Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.18.5. Arkansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.18.6. Arkansas Procedure Volume, ASC and Procurement Dynamics
10.4.19. Kentucky
10.4.19.1. Overview
10.4.19.2. Kentucky Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.19.3. Kentucky Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.4.19.4. Kentucky Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.19.5. Kentucky Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.19.6. Kentucky Procedure Volume, ASC and Procurement Dynamics
10.4.20. Oklahoma
10.4.20.1. Overview
10.4.20.2. Oklahoma Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.20.3. Oklahoma Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.4.20.4. Oklahoma Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.20.5. Oklahoma Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.20.6. Oklahoma Procedure Volume, ASC and Procurement Dynamics
10.4.21. Virginia
10.4.21.1. Overview
10.4.21.2. Virginia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.21.3. Virginia Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.4.21.4. Virginia Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.21.5. Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.21.6. Virginia Procedure Volume, ASC and Procurement Dynamics
10.4.22. Maryland
10.4.22.1. Overview
10.4.22.2. Maryland Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.22.3. Maryland Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.4.22.4. Maryland Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.22.5. Maryland Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.22.6. Maryland Procedure Volume, ASC and Procurement Dynamics
10.4.23. West Virginia
10.4.23.1. Overview
10.4.23.2. West Virginia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.23.3. West Virginia Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.4.23.4. West Virginia Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.23.5. West Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.23.6. West Virginia Procedure Volume, ASC and Procurement Dynamics
10.4.24. Delaware
10.4.24.1. Overview
10.4.24.2. Delaware Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.24.3. Delaware Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.4.24.4. Delaware Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.24.5. Delaware Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.24.6. Delaware Procedure Volume, ASC and Procurement Dynamics
10.4.25. District of Columbia
10.4.25.1. Overview
10.4.25.2. District of Columbia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.25.3. District of Columbia Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.4.25.4. District of Columbia Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.25.5. District of Columbia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.25.6. District of Columbia Procedure Volume and Procurement Dynamics
10.5. Midwest Region
10.5.1. Regional Overview & Trends
10.5.2. Midwest Region GI Endoscopy Key Manufacturers and Procurement Ecosystem
10.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.5.4. Midwest Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.5. Midwest Region Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.5.6. Midwest Region Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.7. Midwest Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.8. Midwest Region Procedure Economics and Procurement Dynamics
10.5.9. Illinois
10.5.9.1. Overview
10.5.9.2. Illinois Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.9.3. Illinois Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.5.9.4. Illinois Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.9.5. Illinois Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.9.6. Illinois Procedure Volume, ASC and Procurement Dynamics
10.5.10. Ohio
10.5.10.1. Overview
10.5.10.2. Ohio Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.10.3. Ohio Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.5.10.4. Ohio Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.10.5. Ohio Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.10.6. Ohio Procedure Volume, ASC and Procurement Dynamics
10.5.11. Michigan
10.5.11.1. Overview
10.5.11.2. Michigan Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.11.3. Michigan Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.5.11.4. Michigan Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.11.5. Michigan Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.11.6. Michigan Procedure Volume, ASC and Procurement Dynamics
10.5.12. Minnesota
10.5.12.1. Overview
10.5.12.2. Minnesota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.12.3. Minnesota Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.5.12.4. Minnesota Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.12.5. Minnesota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.12.6. Minnesota Procedure Volume, ASC and Procurement Dynamics
10.5.13. Indiana
10.5.13.1. Overview
10.5.13.2. Indiana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.13.3. Indiana Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.5.13.4. Indiana Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.13.5. Indiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.13.6. Indiana Procedure Volume, ASC and Procurement Dynamics
10.5.14. Wisconsin
10.5.14.1. Overview
10.5.14.2. Wisconsin Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.14.3. Wisconsin Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.5.14.4. Wisconsin Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.14.5. Wisconsin Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.14.6. Wisconsin Procedure Volume, ASC and Procurement Dynamics
10.5.15. Missouri
10.5.15.1. Overview
10.5.15.2. Missouri Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.15.3. Missouri Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.5.15.4. Missouri Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.15.5. Missouri Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.15.6. Missouri Procedure Volume, ASC and Procurement Dynamics
10.5.16. Iowa
10.5.16.1. Overview
10.5.16.2. Iowa Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.16.3. Iowa Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.5.16.4. Iowa Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.16.5. Iowa Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.16.6. Iowa Procedure Volume, ASC and Procurement Dynamics
10.5.17. Kansas
10.5.17.1. Overview
10.5.17.2. Kansas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.17.3. Kansas Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.5.17.4. Kansas Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.17.5. Kansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.17.6. Kansas Procedure Volume, ASC and Procurement Dynamics
10.5.18. Nebraska
10.5.18.1. Overview
10.5.18.2. Nebraska Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.18.3. Nebraska Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.5.18.4. Nebraska Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.18.5. Nebraska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.18.6. Nebraska Procedure Volume, ASC and Procurement Dynamics
10.5.19. North Dakota
10.5.19.1. Overview
10.5.19.2. North Dakota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.19.3. North Dakota Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.5.19.4. North Dakota Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.19.5. North Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.19.6. North Dakota Procedure Volume, ASC and Procurement Dynamics
10.5.20. South Dakota
10.5.20.1. Overview
10.5.20.2. South Dakota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.20.3. South Dakota Market Size and Forecast, By Procedure/Application, 2021–2035 (US$ Billion)
10.5.20.4. South Dakota Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.20.5. South Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.20.6. South Dakota Procedure Volume, ASC and Procurement Dynamics

What this section provides: This section delivers detailed regional and state-level intelligence across all 50 U.S. states, plus the District of Columbia, helping clients identify gastrointestinal procedure-volume hubs, screening opportunities, ASC clusters, advanced-endoscopy referral markets, technology-adoption hotspots and state-level commercial priorities.

11. U.S. Gastrointestinal Endoscopy Devices Market: Competitive Landscape & Company Profiles

11.1. Market Share Analysis, 2025
11.2. Competitive Benchmarking
11.2.1. Product Portfolio Breadth
11.2.2. U.S. Installed Base
11.2.3. Endotherapy Portfolio Strength
11.2.4. AI and Digital Capability
11.2.5. Single-Use Endoscopy Positioning
11.2.6. Service and Repair Infrastructure
11.2.7. Hospital and ASC Commercial Presence
11.3. Company Positioning Matrix
11.3.1. Leaders
11.3.2. Challengers
11.3.3. Innovators
11.3.4. Emerging Players
11.4. Company Profiles
11.4.1. Olympus Corporation
11.4.2. Boston Scientific Corporation
11.4.3. FUJIFILM Healthcare Americas Corporation
11.4.4. PENTAX Medical / HOYA Corporation
11.4.5. Medtronic
11.4.6. STERIS
11.4.7. Ambu A/S
11.4.8. CONMED Corporation
11.4.9. Cook Medical
11.4.10. Micro-Tech Endoscopy USA
11.4.11. Merit Medical Systems
11.4.12. ERBE USA
11.4.13. Ovesco Endoscopy USA
11.4.14. Creo Medical
11.4.15. EndoGastric Solutions
11.4.16. CapsoVision
11.4.17. AnX Robotica
11.4.18. KARL STORZ Endoscopy-America
11.4.19. Richard Wolf Medical Instruments
11.4.20. Cosmo Intelligent Medical Devices / Cosmo Pharmaceuticals
11.4.21. EvoEndo
11.4.22. CDx Diagnostics
11.4.23. EndoSound

Note: Each company profile will include company overview, gastrointestinal endoscopy device portfolio, U.S. market positioning, product and technology strategy, financial positioning where available, installed-base strategy, FDA regulatory developments, clinical evidence, partnerships, acquisitions, product launches and recent developments.

What this section provides: This section gives clients competitor benchmarking, market-share visibility, portfolio positioning, technology differentiation, U.S. commercialization strategy and strategic intelligence on leading gastrointestinal endoscopy device companies.

12. U.S. Gastrointestinal Endoscopy Devices Market: Future Market Outlook, 2026–2035

12.1. Scenario Analysis
12.1.1. Optimistic Scenario
12.1.2. Realistic Scenario
12.1.3. Pessimistic Scenario
12.2. Disruptive Technologies Impact
12.2.1. AI-Assisted Polyp Detection and Characterization
12.2.2. Quantitative and Computer-Vision Endoscopy
12.2.3. Single-Use Gastrointestinal Endoscopy
12.2.4. Next-Generation Image Enhancement
12.2.5. Therapeutic Endoscopic Ultrasound
12.2.6. Robotic and Computer-Assisted Endoscopy
12.2.7. Advanced Endoluminal Closure and Suturing
12.2.8. Digital Endoscopy Workflow Platforms
12.3. Future Colorectal Screening Impact on Colonoscopy Demand
12.4. Impact of Non-Invasive Screening Technologies
12.5. Future Hospital-to-ASC Procedure Migration
12.6. Future Reusable Versus Single-Use Endoscope Mix
12.7. Emerging Business Models
12.8. Business Opportunities for Startups and Existing Players
12.9. Investment Prioritization Matrix
12.10. High-Growth Technology Opportunity Matrix

What this section provides: This section prepares clients for future changes in clinical technology, procedure migration, screening pathways, device utilization and competitive structure while identifying investment and business opportunities through 2035.

13. U.S. Gastrointestinal Endoscopy Devices Market: Strategic Recommendations

13.1. Recommendations for Gastrointestinal Endoscope Manufacturers
13.2. Recommendations for Endotherapy Device Manufacturers
13.3. Recommendations for AI and Digital Endoscopy Companies
13.4. Recommendations for Hospitals and Integrated Health Systems
13.5. Recommendations for Ambulatory Surgery Centers and Gastroenterology Groups
13.6. Recommendations for Investors and Private Equity Firms
13.7. Recommendations for Distributors and Channel Partners
13.8. Recommendations for New Entrants and Startups
13.9. U.S. Go-to-Market Strategy Considerations
13.9.1. Academic Center Entry Strategy
13.9.2. IDN Contracting Strategy
13.9.3. ASC Commercialization Strategy
13.9.4. Gastroenterologist KOL Strategy
13.9.5. GPO and Distributor Strategy
13.10. Product Positioning and Portfolio Expansion Guidance
13.11. Capital-Consumable Bundling Strategy
13.12. Clinical Evidence and Health-Economic Evidence Strategy
13.13. State-Level Commercial Prioritization Strategy

What this section provides: This section converts the report’s market intelligence into actionable strategies for product positioning, clinical evidence development, hospital and ASC penetration, channel expansion, capital-consumable contracting, investment planning and competitive differentiation.

14. U.S. Gastrointestinal Endoscopy Devices Market: Disclaimer

14.1. Scope Limitation
14.2. Data Use Limitation
14.3. Market Sizing Limitation
14.4. Forecasting Limitation
14.5. Procedure Volume Estimation Limitation
14.6. State-Level Market Estimation Limitation
14.7. Legal Disclaimer
14.8. Third-Party Data Disclaimer

What this section provides: This section defines the report’s scope, methodological limitations, forecast boundaries, state-level estimation limitations, legal conditions and responsible use of market intelligence.

 

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. Gastrointestinal Endoscopy Devices Market: Market Definition and Scope
TABLE 3: U.S. Gastrointestinal Endoscopy Devices Market: Research Methodology Framework
TABLE 4: U.S. Gastrointestinal Endoscopy Devices Market: Key Assumptions
TABLE 5: U.S. Gastrointestinal Endoscopy Devices Market: Market Ecosystem Overview
TABLE 6: U.S. Gastrointestinal Endoscopy Devices Market: Stakeholder Analysis
TABLE 7: U.S. Gastrointestinal Endoscopy Devices Market: Executive Summary Snapshot, 2025
TABLE 8: U.S. Gastrointestinal Endoscopy Devices Market: Analyst Viewpoint Summary
TABLE 9: U.S. Gastrointestinal Endoscopy Devices Market: Market Attractiveness Index
TABLE 10: U.S. Gastrointestinal Endoscopy Devices Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 11: U.S. Gastrointestinal Endoscopy Devices Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 12: U.S. Gastrointestinal Endoscopy Devices Market: Year-wise Market Size, 2021–2035 (US$ Billion)
TABLE 13: U.S. Gastrointestinal Endoscopy Devices Market: High-Growth Opportunity Areas
TABLE 14: U.S. Gastrointestinal Endoscopy Devices Market: Drivers; Impact Analysis
TABLE 15: U.S. Gastrointestinal Endoscopy Devices Market: Restraints; Impact Analysis
TABLE 16: U.S. Gastrointestinal Endoscopy Devices Market: Opportunities; Impact Analysis
TABLE 17: U.S. Gastrointestinal Endoscopy Devices Market: Challenges; Impact Analysis
TABLE 18: U.S. Gastrointestinal Endoscopy Devices Market: Patent & Innovation Analysis, 2021–2025
TABLE 19: U.S. Gastrointestinal Endoscopy Devices Market: Gastrointestinal Endoscopy Procedure Volume Analysis
TABLE 20: U.S. Gastrointestinal Endoscopy Devices Market: Clinical Workflow Economics Matrix
TABLE 21: U.S. Gastrointestinal Endoscopy Devices Market: Hospital and ASC Capital Procurement Behavior Matrix
TABLE 22: U.S. Gastrointestinal Endoscopy Devices Market: Installed-Base Replacement Cycle Analysis
TABLE 23: U.S. Gastrointestinal Endoscopy Devices Market: PESTEL Analysis
TABLE 24: U.S. Gastrointestinal Endoscopy Devices Market: Porter’s Five Forces Analysis
TABLE 25: U.S. Gastrointestinal Endoscopy Devices Market: Pricing Trend Analysis by Region, 2025–2035
TABLE 26: U.S. Gastrointestinal Endoscopy Devices Market: Value Chain Analysis
TABLE 27: U.S. Gastrointestinal Endoscopy Devices Market: Supply Chain Analysis
TABLE 28: U.S. Gastrointestinal Endoscopy Devices Market: Digitalization and Connected Endoscopy Impact
TABLE 29: U.S. Gastrointestinal Endoscopy Devices Market: Clinical Application & Innovation Landscape
TABLE 30: U.S. Gastrointestinal Endoscopy Devices Market: FDA Regulatory Framework Analysis
TABLE 31: U.S. Gastrointestinal Endoscopy Devices Market: CMS Reimbursement and Coverage Landscape
TABLE 32: U.S. Gastrointestinal Endoscopy Devices Market: Import/Export Restrictions & Tariff Impact
TABLE 33: U.S. Gastrointestinal Endoscopy Devices Market: Colorectal Cancer Screening Initiatives
TABLE 34: U.S. Gastrointestinal Endoscopy Devices Market: Geopolitical and Supply-Chain Risk Impact
TABLE 35: U.S. Gastrointestinal Endoscopy Devices Market: Hospital Value Analysis Committee Decision Framework
TABLE 36: U.S. Gastrointestinal Endoscopy Devices Market: Sustainability and Medical Waste Considerations
TABLE 37: U.S. Gastrointestinal Endoscopy Devices Market: Product Type Snapshot, 2025
TABLE 38: Segment Dashboard; Definition and Scope, by Product Type
TABLE 39: U.S. Gastrointestinal Endoscopy Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 40: U.S. Gastrointestinal Endoscopy Devices Market: Segment Share Analysis, by Product Type, 2025 & 2035 (%)
TABLE 41: Reusable Flexible Gastrointestinal Endoscopes Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 42: Single-Use Gastrointestinal Endoscopes Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 43: Visualization and Imaging Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 44: Endoscopic Ultrasound and Capsule Endoscopy Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 45: Endotherapy Devices and Accessories Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 46: U.S. Gastrointestinal Endoscopy Devices Market: Procedure/Application Snapshot, 2025
TABLE 47: Segment Dashboard; Definition and Scope, by Procedure/Application
TABLE 48: U.S. Gastrointestinal Endoscopy Devices Market, by Procedure/Application, 2021–2035 (US$ Billion)
TABLE 49: U.S. Gastrointestinal Endoscopy Devices Market: Segment Share Analysis, by Procedure/Application, 2025 & 2035 (%)
TABLE 50: Colonoscopy, Colorectal Cancer Screening & Polypectomy Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 51: Upper Gastrointestinal Endoscopy Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 52: ERCP and Pancreaticobiliary Intervention Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 53: Endoscopic Ultrasound Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 54: Advanced Therapeutic Endoscopy Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 55: U.S. Gastrointestinal Endoscopy Devices Market: Technology Snapshot, 2025
TABLE 56: Segment Dashboard; Definition and Scope, by Technology
TABLE 57: U.S. Gastrointestinal Endoscopy Devices Market, by Technology, 2021–2035 (US$ Billion)
TABLE 58: U.S. Gastrointestinal Endoscopy Devices Market: Segment Share Analysis, by Technology, 2025 & 2035 (%)
TABLE 59: High-Definition and Image-Enhanced Endoscopy Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 60: AI-Assisted Endoscopy Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 61: Single-Use and Infection-Prevention Technology Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 62: Endoscopic Ultrasound and Interventional Imaging Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 63: Digital Workflow and Quantitative Endoscopy Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 64: U.S. Gastrointestinal Endoscopy Devices Market: End User Snapshot, 2025
TABLE 65: Segment Dashboard; Definition and Scope, by End User
TABLE 66: U.S. Gastrointestinal Endoscopy Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 67: U.S. Gastrointestinal Endoscopy Devices Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 68: Hospitals and Integrated Health Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 69: Ambulatory Surgery Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 70: Gastroenterology Clinics and Dedicated Endoscopy Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 71: Academic Medical Centers and Advanced Endoscopy Referral Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 72: Other Outpatient and Specialized Care Settings Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 73: U.S. Gastrointestinal Endoscopy Devices Market: Clinical Workflow Analysis
TABLE 74: U.S. Gastrointestinal Endoscopy Devices Market: Procedure-Level Cost Analysis
TABLE 75: U.S. Gastrointestinal Endoscopy Devices Market: Reusable vs Single-Use Endoscope Economics
TABLE 76: U.S. Gastrointestinal Endoscopy Devices Market: Endoscope Reprocessing Cost and Capacity Analysis
TABLE 77: U.S. Gastrointestinal Endoscopy Devices Market: Scope Repair, Maintenance and Service Contract Economics
TABLE 78: U.S. Gastrointestinal Endoscopy Devices Market: Capital Equipment Replacement Cycle Analysis
TABLE 79: U.S. Gastrointestinal Endoscopy Devices Market: Hospital, IDN and GPO Procurement Behavior
TABLE 80: U.S. Gastrointestinal Endoscopy Devices Market: ASC Procurement Economics
TABLE 81: U.S. Gastrointestinal Endoscopy Devices Market: Physician Preference and Clinical Evaluation Influence
TABLE 82: U.S. Gastrointestinal Endoscopy Devices Market: Total Cost of Ownership Framework
TABLE 83: U.S. Gastrointestinal Endoscopy Devices Market: Regional Snapshot, 2025
TABLE 84: Segment Dashboard; Definition and Scope, by Geography
TABLE 85: U.S. Gastrointestinal Endoscopy Devices Market, by Region, 2021–2035 (US$ Billion)
TABLE 86: U.S. Gastrointestinal Endoscopy Devices Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 87: West Region U.S. Gastrointestinal Endoscopy Devices Market: Regional Overview and Trends
TABLE 88: West Region U.S. Gastrointestinal Endoscopy Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 89: West Region U.S. Gastrointestinal Endoscopy Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 90: West Region U.S. Gastrointestinal Endoscopy Devices Market: Procedure Volume, ASC and Procurement Dynamics
TABLE 91: California Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 92: Washington Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 93: Arizona Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 94: Colorado Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 95: Oregon Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 96: Utah Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 97: Nevada Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 98: New Mexico Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 99: Idaho Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 100: Montana Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 101: Wyoming Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 102: Alaska Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 103: Hawaii Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 104: Northeast Region U.S. Gastrointestinal Endoscopy Devices Market: Regional Overview and Trends
TABLE 105: Northeast Region U.S. Gastrointestinal Endoscopy Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 106: Northeast Region U.S. Gastrointestinal Endoscopy Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 107: Northeast Region U.S. Gastrointestinal Endoscopy Devices Market: Procedure Volume, ASC and Procurement Dynamics
TABLE 108: New York Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 109: Massachusetts Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 110: New Jersey Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 111: Pennsylvania Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 112: Connecticut Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 113: Maine Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 114: Vermont Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 115: New Hampshire Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 116: Rhode Island Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 117: South Region U.S. Gastrointestinal Endoscopy Devices Market: Regional Overview and Trends
TABLE 118: South Region U.S. Gastrointestinal Endoscopy Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 119: South Region U.S. Gastrointestinal Endoscopy Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 120: South Region U.S. Gastrointestinal Endoscopy Devices Market: Procedure Volume, ASC and Procurement Dynamics
TABLE 121: Texas Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 122: Florida Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 123: Georgia Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 124: North Carolina Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 125: Tennessee Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 126: South Carolina Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 127: Alabama Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 128: Mississippi Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 129: Louisiana Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 130: Arkansas Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 131: Kentucky Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 132: Oklahoma Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 133: Virginia Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 134: Maryland Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 135: West Virginia Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 136: Delaware Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 137: District of Columbia Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 138: Midwest Region U.S. Gastrointestinal Endoscopy Devices Market: Regional Overview and Trends
TABLE 139: Midwest Region U.S. Gastrointestinal Endoscopy Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 140: Midwest Region U.S. Gastrointestinal Endoscopy Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 141: Midwest Region U.S. Gastrointestinal Endoscopy Devices Market: Procedure Volume, ASC and Procurement Dynamics
TABLE 142: Illinois Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 143: Ohio Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 144: Michigan Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 145: Minnesota Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 146: Indiana Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 147: Wisconsin Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 148: Missouri Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 149: Iowa Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 150: Kansas Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 151: Nebraska Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 152: North Dakota Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 153: South Dakota Gastrointestinal Endoscopy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 154: U.S. Gastrointestinal Endoscopy Devices Market: Competitive Landscape Snapshot, 2025
TABLE 155: U.S. Gastrointestinal Endoscopy Devices Market: Key Company Market Share Analysis, 2025
TABLE 156: U.S. Gastrointestinal Endoscopy Devices Market: Company Positioning Matrix
TABLE 157: U.S. Gastrointestinal Endoscopy Devices Market: Product Portfolio Benchmarking of Key Players
TABLE 158: U.S. Gastrointestinal Endoscopy Devices Market: Strategic Developments, Partnerships, M&A and Product Launches
TABLE 159: Olympus Corporation: Company Profile
TABLE 160: Boston Scientific Corporation: Company Profile
TABLE 161: FUJIFILM Healthcare Americas Corporation: Company Profile
TABLE 162: PENTAX Medical / HOYA Corporation: Company Profile
TABLE 163: Medtronic: Company Profile
TABLE 164: STERIS: Company Profile
TABLE 165: Ambu A/S: Company Profile
TABLE 166: CONMED Corporation: Company Profile
TABLE 167: Cook Medical: Company Profile
TABLE 168: Micro-Tech Endoscopy USA: Company Profile
TABLE 169: Merit Medical Systems: Company Profile
TABLE 170: ERBE USA: Company Profile
TABLE 171: Ovesco Endoscopy USA: Company Profile
TABLE 172: Creo Medical: Company Profile
TABLE 173: EndoGastric Solutions: Company Profile
TABLE 174: CapsoVision: Company Profile
TABLE 175: AnX Robotica: Company Profile
TABLE 176: KARL STORZ Endoscopy-America: Company Profile
TABLE 177: Richard Wolf Medical Instruments: Company Profile
TABLE 178: Cosmo Intelligent Medical Devices / Cosmo Pharmaceuticals: Company Profile
TABLE 179: EvoEndo: Company Profile
TABLE 180: CDx Diagnostics: Company Profile
TABLE 181: EndoSound: Company Profile
TABLE 182: U.S. Gastrointestinal Endoscopy Devices Market: Future Market Scenario Analysis, 2026–2035
TABLE 183: U.S. Gastrointestinal Endoscopy Devices Market: Disruptive Technologies Impact Matrix
TABLE 184: U.S. Gastrointestinal Endoscopy Devices Market: Colorectal Screening and Colonoscopy Demand Outlook
TABLE 185: U.S. Gastrointestinal Endoscopy Devices Market: Hospital-to-ASC Procedure Migration Outlook
TABLE 186: U.S. Gastrointestinal Endoscopy Devices Market: Reusable vs Single-Use Endoscope Mix Outlook
TABLE 187: U.S. Gastrointestinal Endoscopy Devices Market: Emerging Business Trends
TABLE 188: U.S. Gastrointestinal Endoscopy Devices Market: Business Opportunities for Startups and Existing Players
TABLE 189: U.S. Gastrointestinal Endoscopy Devices Market: Investment Prioritization Matrix
TABLE 190: U.S. Gastrointestinal Endoscopy Devices Market: Strategic Recommendations for Endoscope Manufacturers
TABLE 191: U.S. Gastrointestinal Endoscopy Devices Market: Strategic Recommendations for Endotherapy Device Manufacturers
TABLE 192: U.S. Gastrointestinal Endoscopy Devices Market: Strategic Recommendations for Hospitals and Health Systems
TABLE 193: U.S. Gastrointestinal Endoscopy Devices Market: Strategic Recommendations for ASCs and Gastroenterology Groups
TABLE 194: U.S. Gastrointestinal Endoscopy Devices Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 195: U.S. Gastrointestinal Endoscopy Devices Market: Strategic Recommendations for Distributors and Channel Partners
TABLE 196: U.S. Gastrointestinal Endoscopy Devices Market: Strategic Recommendations for New Entrants and Startups
TABLE 197: U.S. Gastrointestinal Endoscopy Devices Market: Go-to-Market Strategy Considerations
TABLE 198: U.S. Gastrointestinal Endoscopy Devices Market: Product Positioning and Portfolio Expansion Guidance
TABLE 199: U.S. Gastrointestinal Endoscopy Devices Market: Scope Limitation
TABLE 200: U.S. Gastrointestinal Endoscopy Devices Market: Data Use Limitation
TABLE 201: U.S. Gastrointestinal Endoscopy Devices Market: Market Sizing Limitation
TABLE 202: U.S. Gastrointestinal Endoscopy Devices Market: Forecasting Limitation
TABLE 203: U.S. Gastrointestinal Endoscopy Devices Market: State-Level Market Estimation Limitation
TABLE 204: U.S. Gastrointestinal Endoscopy Devices Market: Legal and Third-Party Data Disclaimer

List of Figures

FIGURE 1: U.S. Gastrointestinal Endoscopy Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: Market Ecosystem and Stakeholder Framework
FIGURE 4: U.S. Gastrointestinal Endoscopy Devices Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 5: U.S. Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 6: U.S. Gastrointestinal Endoscopy Devices Market Year-wise Growth Curve, 2021–2035
FIGURE 7: Market Attractiveness Analysis
FIGURE 8: Market Dynamics
FIGURE 9: Innovation & Patent Landscape, 2021–2025
FIGURE 10: U.S. Gastrointestinal Endoscopy Procedure Volume Framework
FIGURE 11: Clinical Workflow Economics Framework
FIGURE 12: Hospital and ASC Capital Procurement Decision Framework
FIGURE 13: PESTEL Analysis
FIGURE 14: Porter’s Five Forces Analysis
FIGURE 15: Value Chain Analysis
FIGURE 16: Supply Chain Analysis
FIGURE 17: FDA Regulatory and CMS Reimbursement Framework
FIGURE 18: Sustainability and Medical Waste Impact Framework
FIGURE 19: Product Type Segment Market Share Analysis, 2025 & 2035
FIGURE 20: Product Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 21: Reusable Flexible Gastrointestinal Endoscopes Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 22: Single-Use Gastrointestinal Endoscopes Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 23: Visualization and Imaging Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 24: Endoscopic Ultrasound and Capsule Endoscopy Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 25: Endotherapy Devices and Accessories Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 26: Procedure/Application Segment Market Share Analysis, 2025 & 2035
FIGURE 27: Procedure/Application Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 28: Colonoscopy, Colorectal Cancer Screening & Polypectomy Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 29: Upper Gastrointestinal Endoscopy Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 30: ERCP and Pancreaticobiliary Intervention Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 31: Endoscopic Ultrasound Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 32: Advanced Therapeutic Endoscopy Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 33: Technology Segment Market Share Analysis, 2025 & 2035
FIGURE 34: Technology Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 35: High-Definition and Image-Enhanced Endoscopy Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 36: AI-Assisted Endoscopy Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 37: Single-Use and Infection-Prevention Technology Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 38: Endoscopic Ultrasound and Interventional Imaging Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 39: Digital Workflow and Quantitative Endoscopy Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 40: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 41: End User Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 42: Hospitals and Integrated Health Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 43: Ambulatory Surgery Centers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 44: Gastroenterology Clinics and Dedicated Endoscopy Centers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 45: Academic Medical Centers and Advanced Endoscopy Referral Centers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 46: Other Outpatient and Specialized Care Settings Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 47: Gastrointestinal Endoscopy Clinical Workflow Map
FIGURE 48: Procedure-Level Cost Comparison Framework
FIGURE 49: Reusable vs Single-Use Endoscope Economics
FIGURE 50: Endoscope Reprocessing Cost and Capacity Framework
FIGURE 51: Scope Repair, Maintenance and Service Economics
FIGURE 52: Capital Equipment Replacement Cycle
FIGURE 53: Hospital, IDN and GPO Procurement Framework
FIGURE 54: ASC Procurement Economics Framework
FIGURE 55: Total Cost of Ownership Framework
FIGURE 56: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 57: Regional Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 58: West Region U.S. Gastrointestinal Endoscopy Devices Market Share and Leading Players, 2025
FIGURE 59: West Region Market Share Analysis by State, 2025
FIGURE 60: West Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 61: California Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 62: Washington Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 63: Arizona Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 64: Colorado Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 65: Oregon Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 66: Utah Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 67: Nevada Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 68: New Mexico Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 69: Idaho Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 70: Montana Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 71: Wyoming Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 72: Alaska Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 73: Hawaii Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 74: Northeast Region U.S. Gastrointestinal Endoscopy Devices Market Share and Leading Players, 2025
FIGURE 75: Northeast Region Market Share Analysis by State, 2025
FIGURE 76: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 77: New York Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 78: Massachusetts Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 79: New Jersey Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 80: Pennsylvania Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 81: Connecticut Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 82: Maine Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 83: Vermont Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 84: New Hampshire Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 85: Rhode Island Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 86: South Region U.S. Gastrointestinal Endoscopy Devices Market Share and Leading Players, 2025
FIGURE 87: South Region Market Share Analysis by State, 2025
FIGURE 88: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 89: Texas Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 90: Florida Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 91: Georgia Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 92: North Carolina Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 93: Tennessee Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 94: South Carolina Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 95: Alabama Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 96: Mississippi Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 97: Louisiana Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 98: Arkansas Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 99: Kentucky Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 100: Oklahoma Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 101: Virginia Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 102: Maryland Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 103: West Virginia Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 104: Delaware Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 105: District of Columbia Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 106: Midwest Region U.S. Gastrointestinal Endoscopy Devices Market Share and Leading Players, 2025
FIGURE 107: Midwest Region Market Share Analysis by State, 2025
FIGURE 108: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 109: Illinois Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 110: Ohio Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 111: Michigan Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 112: Minnesota Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 113: Indiana Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 114: Wisconsin Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 115: Missouri Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 116: Iowa Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 117: Kansas Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 118: Nebraska Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 119: North Dakota Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 120: South Dakota Gastrointestinal Endoscopy Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 121: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 122: Company Positioning Matrix
FIGURE 123: Key Player Product Portfolio Benchmarking
FIGURE 124: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 125: Gastrointestinal Endoscopy Device Innovation Roadmap
FIGURE 126: AI-Assisted Endoscopy Adoption Roadmap
FIGURE 127: Single-Use Endoscopy Opportunity Map
FIGURE 128: Advanced Therapeutic Endoscopy Growth Roadmap
FIGURE 129: Future Market Scenario Analysis, 2026–2035
FIGURE 130: Disruptive Technologies Impact Matrix
FIGURE 131: Colorectal Screening and Colonoscopy Demand Outlook
FIGURE 132: Hospital-to-ASC Procedure Migration Outlook
FIGURE 133: Reusable vs Single-Use Endoscope Mix Outlook
FIGURE 134: Emerging Business Trends Matrix
FIGURE 135: Investment Prioritization Matrix
FIGURE 136: Strategic Growth Roadmap for U.S. Gastrointestinal Endoscopy Device Companies
FIGURE 137: Go-to-Market Strategy Framework
FIGURE 138: Product Positioning and Portfolio Expansion Framework
FIGURE 139: Report Scope and Disclaimer Framework